Who
Uneek Mehra
Other role
Company insider
Files Form 4 as: Chief Financial Officer, BridgeBio Oncology Therapeutics; Officer, 4D Molecular Therapeutics; Principal Financial Officer, Myovant Sciences.
In numbers
- Trades disclosed
- 19
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $234K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 15 Sep 2021
- Last trade
- 1 Apr 2026
- Last filed
- 5 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Apr 2026filed 5 May 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code F | $4,732524 at $9.03 | filing |
| 1 Apr 2026filed 5 May 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code F | $4,732524 at $9.03 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code A | —23,330 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code A | —23,330 at $0.00 | filing |
| 26 Aug 2025filed 28 Aug 2025 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —633,570 at $0.00 | filing |
| 6 Mar 2025filed 10 Mar 2025 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 11 Dec 2023filed 13 Dec 2023 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Oct 2023filed 3 Oct 2023 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —229,634 at $0.00 | filing |
| 10 Mar 2023filed 10 Mar 2023 | Myovant Sciencesoption or derivative | SEC FORM 4 Code D | —165,192 | filing |
| 10 Mar 2023filed 10 Mar 2023 | Myovant Sciencesoption or derivative | SEC FORM 4 Code D | —111,111 | filing |
| 10 Mar 2023filed 10 Mar 2023 | Myovant Sciences | SEC FORM 4 Code D | —20,724 | filing |
| 10 Mar 2023filed 10 Mar 2023 | Myovant Sciences | SEC FORM 4 Code D | —181,972 | filing |
| 16 Dec 2022filed 20 Dec 2022 | Myovant Sciences | SEC FORM 4 Sold | $60K2,241 at $26.75 | filing |
| 16 Sep 2022filed 20 Sep 2022 | Myovant Sciences | SEC FORM 4 Sold | $174K9,243 at $18.86 | filing |
| 15 Apr 2022filed 19 Apr 2022 | Myovant Sciences | SEC FORM 4 Code A | —111,111 at $0.00 | filing |
| 15 Sep 2021filed 17 Sep 2021 | Myovant Sciencesoption or derivative | SEC FORM 4 Code A | —165,192 at $0.00 | filing |
| 15 Sep 2021filed 17 Sep 2021 | Myovant Sciences | SEC FORM 4 Code A | —103,069 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.